- Infection is a Major Unmet Need in Plastic and Reconstructive Surgery: Infection risk was cited in all 11 breast research sessions at the American Society of Plastic Surgeons’ annual meeting, with serious infection rates reported as high as 23%.
- NXT-41x In Vivo Study Supports Planned Q4 2026 FDA Submission: The GLP rabbit antibacterial study achieved its prespecified performance endpoints, with no viable bacteria recovered after either the 8-log MRSA challenges or the 6-log E. coli challenges, demonstrating robust eradication of relevant pathogens.
- $26 Million in Capital Received: Elutia added $26 million without an equity offering, which is expected to fund the company through the anticipated clearance and first full-year of NXT-41x commercialization in 2028.
- Cardiovascular Revenue Grows 20%: Elutia’s cardiovascular business delivered 20% year-over-year revenue growth in the third quarter of 2026 and 65% growth for the first nine months of 2026.
GAITHERSBURG, Md., Nov. 05, 2026 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a drug delivery company built to stop surgical infections, today provided a business update and announced financial results for the third quarter ended September 30, 2026.
Infection Has Become a Major Focus at ASPS. No Commercial Product Addresses It.
At Plastic Surgery The Meeting 2026 (PSTM 2026), the annual meeting of the American Society of Plastic Surgeons held October 15 to 18 in Houston, the program highlighted a major gap between the prevalence and severity of surgical infections and the lack of products to address them.
Infection risk and prevention were discussed in all 11 breast research sessions, and 70 of 135 (51.9%) oral research presentations addressed infection.
Infection is common despite current best practices. Independent investigators presented data at the meeting showing:
- In a study of 1,094 breasts undergoing immediate implant-based surgery, infection rates were 17.6% in women who did not receive chemotherapy before surgery and 23.0% in those who did (Lopes A, et al., PSTM 2026).
- Another study of 419 breasts treated with perioperative and postoperative antibiotics found infection rates of 19.3% (Fernandez K et al., PSTM 2026).
More systemic antibiotics do not help. In a multicenter study of 4,647 patients at 170 healthcare organizations, extending antibiotics past 24 hours did not reduce infection at 30, 60 or 90 days (Yadav K, et al., PSTM 2026).
The gap on the floor. Despite the intense focus on infection across the scientific program, no commercially available product on the exhibit floor addressed infection in breast surgery. Elutia is developing NXT-41x to address this gap and deliver localized antibiotic therapy directly to the surgical site in reconstructive surgery.
NXT-41x Heads to FDA This Quarter
The FDA review of NXT-41 (biologic surgical matrix without drug) remains on track, with a clearance decision anticipated this quarter. Elutia also intends to submit NXT-41x, its leading drug delivery program, to FDA in the fourth quarter of 2026, following positive results from a key performance study supporting the submission.
NXT-41x demonstrates potent antibacterial activity. NXT-41x is a biologic matrix with an antibiotic coating on one side only. In a GLP rabbit study of infection, the bacterial challenge was applied directly to the uncoated side, a worst-case test. NXT-41x met its predetermined performance endpoints, achieving complete eradication of an 8-log MRSA and a 6-log E. coli challenge, with no viable bacteria recovered from either the matrix or the surrounding tissue. By contrast, 100% of animals implanted with a matrix without antibiotics developed heavy colonization by the offending pathogens. MRSA, short for methicillin-resistant Staphylococcus aureus, is a highly drug-resistant form of the most common pathogen in breast surgery, making these results especially relevant to surgeons and patients.
Source: Elutia, investors.elutia.com. Republished with credit to the original author. Read the original release.
